Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 208

Similar articles for PubMed (Select 18285564)

1.

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH.

Circulation. 2008 Mar 11;117(10):1261-8. doi: 10.1161/CIRCULATIONAHA.107.735605. Epub 2008 Feb 19.

2.

Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.

Ito K, Elkin E, Blinder V, Keating N, Choudhry N.

Cancer. 2013 Jul 1;119(13):2494-502. doi: 10.1002/cncr.28084. Epub 2013 Apr 23.

3.

Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.

Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S.

Ann Intern Med. 2005 Jul 19;143(2):89-99.

PMID:
16027450
4.

Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?

Moran A, Goldman L.

Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):606-7. doi: 10.1038/ncpcardio1309. Epub 2008 Aug 12.

PMID:
18695697
5.

Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis.

Choudhry NK, Avorn J, Antman EM, Schneeweiss S, Shrank WH.

Health Aff (Millwood). 2007 Jan-Feb;26(1):186-94.

6.

Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.

Wang M, Moran AE, Liu J, Coxson PG, Heidenreich PA, Gu D, He J, Goldman L, Zhao D.

Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):78-85. doi: 10.1161/CIRCOUTCOMES.113.000674. Epub 2014 Jan 14.

7.

Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction.

Ito K, Avorn J, Shrank WH, Toscano M, Spettel C, Brennan T, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2015 May;8(3):252-9. doi: 10.1161/CIRCOUTCOMES.114.001330. Epub 2015 May 5.

PMID:
25944633
8.

Health and economic benefits of increased beta-blocker use following myocardial infarction.

Phillips KA, Shlipak MG, Coxson P, Heidenreich PA, Hunink MG, Goldman PA, Williams LW, Weinstein MC, Goldman L.

JAMA. 2000 Dec 6;284(21):2748-54.

PMID:
11105180
9.

Cost-utility of aspirin and proton pump inhibitors for primary prevention.

Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M.

Arch Intern Med. 2011 Feb 14;171(3):218-25. doi: 10.1001/archinternmed.2010.525.

10.

Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies.

Choudhry NK, Brennan T, Toscano M, Spettell C, Glynn RJ, Rubino M, Schneeweiss S, Brookhart AM, Fernandes J, Mathew S, Christiansen B, Antman EM, Avorn J, Shrank WH.

Am Heart J. 2008 Jul;156(1):31-6. doi: 10.1016/j.ahj.2008.03.021. Epub 2008 Jun 6.

11.

Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.

Ganz DA, Kuntz KM, Jacobson GA, Avorn J.

Ann Intern Med. 2000 May 16;132(10):780-7. Erratum in: Ann Intern Med 2002 Apr 16;136(8):635.

PMID:
10819700
12.

Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000.

PMID:
22667992
13.

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ.

Ann Intern Med. 2006 Mar 7;144(5):326-36.

PMID:
16520473
14.

Full coverage for preventive medications after myocardial infarction.

Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, Reisman L, Fernandes J, Spettell C, Lee JL, Levin R, Brennan T, Shrank WH; Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial.

N Engl J Med. 2011 Dec 1;365(22):2088-97. doi: 10.1056/NEJMsa1107913. Epub 2011 Nov 14.

16.

Disability, race/ethnicity, and medication adherence among Medicare myocardial infarction survivors.

Zhang Y, Baik SH, Chang CC, Kaplan CM, Lave JR.

Am Heart J. 2012 Sep;164(3):425-433.e4. doi: 10.1016/j.ahj.2012.05.021. Epub 2012 Aug 3.

17.

Full prescription coverage versus usual prescription coverage after coronary artery bypass graft surgery: analysis from the post-myocardial infarction free Rx event and economic evaluation (FREEE) randomized trial.

Kulik A, Desai NR, Shrank WH, Antman EM, Glynn RJ, Levin R, Reisman L, Brennan T, Choudhry NK.

Circulation. 2013 Sep 10;128(11 Suppl 1):S219-25. doi: 10.1161/CIRCULATIONAHA.112.000337.

18.
19.

Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction.

Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G.

Circulation. 2014 Feb 18;129(7):754-63. doi: 10.1161/CIRCULATIONAHA.113.002658. Epub 2013 Dec 10.

20.

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.

Schleinitz MD, Weiss JP, Owens DK.

Am J Med. 2004 Jun 15;116(12):797-806.

PMID:
15178495
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk